In boost to GSK's £3B plan for Blenrep, myeloma ADC shows survival edge over J&J's Darzalex
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win. The antibody-drug conjugate (ADC) has mounted a statistically significant and clinically meaningful …